Argent Capital Management LLC Takes Position in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU)

Argent Capital Management LLC bought a new stake in shares of InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) in the first quarter, HoldingsChannel.com reports. The institutional investor bought 16,330 shares of the medical instruments supplier’s stock, valued at approximately $332,000.

A number of other hedge funds have also made changes to their positions in INFU. Meeder Asset Management Inc. bought a new position in InfuSystem in the first quarter worth about $38,000. Citigroup Inc. lifted its stake in shares of InfuSystem by 261.6% in the 4th quarter. Citigroup Inc. now owns 2,828 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 2,046 shares during the period. Reby Advisors LLC bought a new stake in shares of InfuSystem during the fourth quarter valued at approximately $66,000. CWM LLC purchased a new stake in InfuSystem in the first quarter worth $68,000. Finally, Rhumbline Advisers bought a new position in InfuSystem in the fourth quarter worth $203,000. 61.58% of the stock is owned by institutional investors.

In other InfuSystem news, Director Paul Andrew Gendron acquired 3,000 shares of InfuSystem stock in a transaction that occurred on Thursday, March 25th. The stock was bought at an average cost of $20.34 per share, for a total transaction of $61,020.00. Following the acquisition, the director now owns 25,000 shares of the company’s stock, valued at $508,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregg Owen Lehman sold 9,708 shares of the business’s stock in a transaction dated Tuesday, March 23rd. The stock was sold at an average price of $21.20, for a total value of $205,809.60. Following the completion of the transaction, the director now directly owns 21,525 shares of the company’s stock, valued at approximately $456,330. The disclosure for this sale can be found here. 18.20% of the stock is currently owned by company insiders.

Separately, Northland Securities began coverage on shares of InfuSystem in a research report on Monday, April 26th. They issued an “outperform” rating and a $27.00 target price on the stock.

InfuSystem stock opened at $20.27 on Friday. InfuSystem Holdings Inc. has a twelve month low of $10.31 and a twelve month high of $23.26. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.93 and a quick ratio of 1.67. The stock has a market cap of $414.91 million, a P/E ratio of 23.85 and a beta of 0.97. The stock has a 50 day moving average of $15.93.

InfuSystem (NYSEAMERICAN:INFU) last issued its quarterly earnings results on Thursday, May 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $24.46 million for the quarter, compared to the consensus estimate of $24.50 million. InfuSystem had a net margin of 18.36% and a return on equity of 52.87%. Research analysts predict that InfuSystem Holdings Inc. will post 0.34 earnings per share for the current fiscal year.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

Featured Article: Is a Roth IRA right for you?

Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings Inc. (NYSEAMERICAN:INFU).

Institutional Ownership by Quarter for InfuSystem (NYSEAMERICAN:INFU)

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.